Voriconazole Camphor Sulfonate

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H14F3N5O.C10H16O4S
Molecular Weight	581.607
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of Voriconazole Camphor Sulfonate

Structure Search

SMILES

CC1(C)[C@H]2CC[C@]1(CS(O)(=O)=O)C(=O)C2.C[C@@H](C3=NC=NC=C3F)[C@](O)(CN4C=NC=N4)C5=CC=C(F)C=C5F

InChI

InChIKey=AMYMCJHOGKVJHB-CRFUWKMFSA-N

InChI=1S/C16H14F3N5O.C10H16O4S/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18;1-9(2)7-3-4-10(9,8(11)5-7)6-15(12,13)14/h2-5,7-10,25H,6H2,1H3;7H,3-6H2,1-2H3,(H,12,13,14)/t10-,16+;7-,10-/m00/s1

HIDE SMILES / InChI

Molecular Formula	C10H16O4S
Molecular Weight	232.297
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	( - )

Molecular Formula	C16H14F3N5O
Molecular Weight	349.3105
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021466lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00582

Voriconazole (vor-i-KON-a-zole, brand name Vfend, Pfizer) is a triazole antifungal medication. VFEND® (voriconazole) is available as film-coated tablets for oral administration, and as a lyophilized powder for solution for intravenous infusion. Voriconazole is a triazole antifungal agent indicated for use in the treatment of fungal infections including invasive aspergillosis, esophageal candidiasis, and serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani. Fungal plasma membranes are similar to mammalian plasma membranes, differing in having the nonpolar sterol ergosterol, rather than cholesterol, as the principal sterol. Membrane sterols such as ergosterol provide structure, modulation of membrane fluidity, and possibly control of some physiologic events. Voriconazole effects the formation of the fungal plasma membrane by indirectly inhibiting the biosynthesis of ergosterol. This results in plasma membrane permeability changes and inhibition of growth. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the antifungal activity of voriconazole. Voriconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems. The most common side effects associated with voriconazole include transient visual disturbances, fever, rash, vomiting, nausea, diarrhea, headache, sepsis, peripheral edema, abdominal pain, and respiratory disorder. Unlike most adverse effects, which are similar to other azole antifungal agents, visual disturbances (such as blurred vision or increased sensitivity to light) are unique to voriconazole. Though rare, there have been cases of serious hepatic reactions during treatment with voriconazole (a class effect of azole antifungal agents). Liver function tests should be evaluated at the start of and during the course of therapy. Voriconazole is phototoxic. It has been associated with an increased risk of squamous-cell carcinoma of the skin

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cytochrome P450 51 28 Target ID: CHEMBL1780 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021466lbl.pdf	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Invasive aspergillosis 15 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021466lbl.pdf	Curative	Approved 8583	VFEND Approved Use use in the treatment of the fungal infections Launch Date 2003
Esophageal candidiasis 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021466lbl.pdf	Curative	Approved 8583	VFEND Approved Use use in the treatment of the fungal infections Launch Date 2003
Scedosporium apiospermum infection 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021466lbl.pdf	Curative	Approved 8583	VFEND Approved Use use in the treatment of the fungal infections Launch Date 2003
Fusarium spp. 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021466lbl.pdf	Curative	Approved 8583	VFEND Approved Use use in the treatment of the fungal infections Launch Date 2003

C_max

Value	Dose	Analyte	Population
3.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933807	200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	VORICONAZOLE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.13 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.03 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	3 mg/kg 2 times / day steady-state, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.77 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	4 mg/kg 2 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.3 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.31 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.74 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	300 mg 2 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
27.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933807	200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	VORICONAZOLE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.9 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
13.7 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	3 mg/kg 2 times / day steady-state, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
33.9 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	4 mg/kg 2 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
9.31 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.4 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
34 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	300 mg 2 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
15.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933807	200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		VORICONAZOLE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
42% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
42% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	300 mg 2 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:		VORICONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	substrate 1193 inhibitor 2438	substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 P-gp 1741 BCRP 910 BSEP 550 UGT2B 3	CYP2C19 1119 CYP1A2 1197 CYP2E1 729

Drug as perpetrator

Target	Modality	Activity
UGT2B 3	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23653047/ Page: 17.0	likely
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17518356/	no
BSEP 554	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27001813/	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_VFEND_biopharmr.pdf Page: 12, 13, 14	yes [Ki 14 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_VFEND_biopharmr.pdf Page: 12, 13, 14	yes [Ki 22 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_VFEND_biopharmr.pdf Page: 12, 13, 14	yes [Ki 7 uM]
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23084335/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021630s000_Vfend_ClinPharm.pdf Page: 2, 10,13, 21-23, 26-27	major	yes (co-administration study) Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96% and fluconazole increased voriconazole Cmax by 57% and AUC 79% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021630s000_Vfend_ClinPharm.pdf Page: 2, 10,13, 21-23, 26-27
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_VFEND_biopharmr.pdf Page: 12.0	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_VFEND_biopharmr.pdf Page: 12.0	no
CYP2E1 729	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_VFEND_biopharmr.pdf Page: 12.0	no
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_VFEND_biopharmr.pdf Page: 11.0	yes [Km 21 uM]	yes (co-administration study) Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96%; fluconazole increased voriconazole Cmax by 57% and AUC 79% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_VFEND_biopharmr.pdf Page: 11.0
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_VFEND_biopharmr.pdf Page: 11.0	yes [Km 240 uM]	yes (co-administration study) Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96%; fluconazole increased voriconazole Cmax by 57% and AUC 79% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-266_VFEND_biopharmr.pdf Page: 11.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:10023	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:10023
ChemicalBook	CB01123117	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB01123117
ChemicalBook	CB1160110	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1160110
eMolecules	30100386	https://www.emolecules.com/cgi-bin/more?vid=30100386
eMolecules	30487979	https://www.emolecules.com/cgi-bin/more?vid=30487979
eMolecules	902682	https://www.emolecules.com/cgi-bin/more?vid=902682
MolPort	MolPort-003-850-863	https://www.molport.com/shop/molecule-link/MolPort-003-850-863
Selleck Chemicals	Voriconazole	http://www.selleckchem.com/products/Voriconazole.html
ZINC	ZINC000000014864	http://zinc15.docking.org/substances/ZINC000000014864

PubMed

Title	Date	PubMed
Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii.	2003-08	12606318
Voriconazole: a new triazole antifungal agent.	2003-03-01	12594645
Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine.	2003-02	12627286
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.	2003-02	12614985
Antifungal pharmacotherapy for invasive mould infections.	2003-02	12562305
Arthritis and osteomyelitis due to Aspergillus fumigatus: a 17 years old boy with chronic granulomatous disease.	2003-01-31	12605719
Disseminated infection due to Cylindrocarpon (Fusarium) lichenicola in a neutropenic patient with acute leukaemia: report of a case and review of the literature.	2003-01	12582748
In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.	2003-01	12517829
Activity of voriconazole against corneal isolates of Scedosporium apiospermum.	2003-01	12502945
In vitro susceptibilities of zygomycetes to conventional and new antifungals.	2003-01	12493786
Voriconazole versus amphotericin B for invasive aspergillosis.	2002-12-19	12494937
Voriconazole versus amphotericin B for invasive aspergillosis.	2002-12-19	12490695
Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.	2002-12	12525928
Usefulness of a colorimetric method for testing antifungal drug susceptibilities of Aspergillus species to voriconazole.	2002-12	12525904
Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.	2002-12	12476292
Case Reports. Chronic and acute Aspergillus meningitis.	2002-12	12472730
[Antifungal treatments].	2002-11-30	12497718
The safety of voriconazole.	2002-11-15	12410490
An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis.	2002-11-01	12384856
Gateways to clinical trials.	2002-11	12616707
In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592).	2002-11	12421285
Voriconazole treatment of disseminated paecilomyces infection in a patient with acquired immunodeficiency syndrome.	2002-10-01	12228840
In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results.	2002-10	12234865
Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry.	2002-09-05	12138003
Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature.	2002-09	12352630
Cerebral aspergillosis caused by Neosartorya hiratsukae, Brazil.	2002-09	12194781
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.	2002-08-08	12167683
Voriconazole.	2002-07-22	12138377
In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.	2002-07	12096017
Fungal keratitis caused by Scedosporium apiospermum: report of two cases and review of treatment.	2002-07	12072730
Severe keratomycosis secondary to Scedosporium apiospermum.	2002-07	12072729
Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.	2002-07	12069979
New drugs, old drugs - dear drugs, cheap drugs.	2002-06-15	12362279
Effect of medium composition on static and cidal activity of amphotericin B, itraconazole, voriconazole, posaconazole and terbinafine against Aspergillus fumigatus: a multicenter study.	2002-06	12120878
Invasive Aspergillus infections in hematologic malignancy patients.	2002-06	12070828
Voriconazole -- better chances for patients with invasive mycoses.	2002-05-31	12069915
Management of mycoses in patients with hematologic disease and cancer -- review of the literature.	2002-05-31	12069913
Management of mycoses in surgical patients -- review of the literature.	2002-05-31	12069912
Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.	2002-05-30	12041527
Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.	2002-05-30	12041526
Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.	2002-05-30	12037157
Broth medium for microdilution susceptibility tests of fluconazole and voriconazole.	2002-05	12072930
Gateways to Clinical Trials.	2002-04	12087878
Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategies.	2002	12611078
Pharmacological aspects of the new triazole voriconazole.	2002	12611077
Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole.	2002	12523628
Successful treatment of Candida glabrata myocarditis with voriconazole.	2002	12477337
Voriconazole: in the treatment of invasive aspergillosis.	2002	12466006
Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole.	2002	12374371
Influence of voriconazole and fluconazole on Candida albicans in long-time continuous flow culture.	2002	12073562

Patents

Sample Use Guides

In Vivo Use Guide

Tablets should be taken at least one hour before, or one hour following, a meal.

Route of Administration: Oral

In Vitro Use Guide

each microdilution well containing 100 ul of the drug concentrations was inoculated with 100 ul of the diluted inoculum suspension (final volume in each well was 200 ul). Drug concentrations were 0.03 to 16 mg/ml for voriconazole. Stock inoculum suspensions of the molds were prepared from 7-day (Aspergillus spp., Bipolaris spp., P. boydii, R. arrhizus, and S. schenckii) or 7- to 10-day (B. dermatitidis and H. capsulatum) cultures grown on PDA at 35°C (cultures for Fusarium spp. were grown at 35°C for 48 to 72 h and then at 25 to 28°C until day 7

Substance Class	Chemical Created by `admin` on `Wed Apr 02 14:34:47 GMT 2025` Edited by `admin` on `Wed Apr 02 14:34:47 GMT 2025`
Record UNII	WQ4A6X26NY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Voriconazole Camphor Sulfonate

Common Name

English

4-Pyrimidineethanol, ?-(2,4-difluorophenyl)-5-fluoro-?-methyl-?-(1H-1,2,4-triazol-1-ylmethyl)-, (?R,?S)-, mono[(1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonate]

Preferred Name

English

Code System Code Type Description

CAS

137234-71-0

Created by admin on Wed Apr 02 14:34:47 GMT 2025 , Edited by admin on Wed Apr 02 14:34:47 GMT 2025

PRIMARY

SMS_ID

300000053622

Created by admin on Wed Apr 02 14:34:47 GMT 2025 , Edited by admin on Wed Apr 02 14:34:47 GMT 2025

PRIMARY

PUBCHEM

23658063

Created by admin on Wed Apr 02 14:34:47 GMT 2025 , Edited by admin on Wed Apr 02 14:34:47 GMT 2025

PRIMARY

FDA UNII

WQ4A6X26NY

Created by admin on Wed Apr 02 14:34:47 GMT 2025 , Edited by admin on Wed Apr 02 14:34:47 GMT 2025

PRIMARY

Related Record Type Details


					JFU09I87TR

VORICONAZOLE

PARENT -> SALT/SOLVATE

Amount:

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021466lbl.pdfCurator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00582

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021466lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00582

C_max

T_1/2

F_unbound

Drug as perpetrator